Sugi Predict

Sugi Predict / Compounds / SCHEMBL322187

SCHEMBL322187

SCHEMBL322187

COc1ccc(CNc2ccc(F)cn2)c(OC)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP1A2 P05177 15/20 0.58
▸ CYP3A4 P08684 15/20 0.58
▸ CYP2D6 P10635 14/20 0.58
▸ CYP2C19 P33261 14/20 0.58
▸ TSHR P16473 13/20 0.58
▸ USP2 O75604 6/20 0.58
▸ MEN1 O00255 3/20 0.58
▸ KMT2A Q03164 3/20 0.58
▸ CLK4 Q9HAZ1 9/20 0.56
▸ MAPK1 P28482 5/20 0.56
▸ HSD17B10 Q99714 5/20 0.56
▸ ALOX15 P16050 3/20 0.56
▸ APLNR P35414 1/20 0.54
▸ LMNA P02545 7/20 0.53
▸ ALDH1A1 P00352 6/20 0.53
▸ ATM Q13315 1/20 0.52
▸ CYP2C9 P11712 3/20 0.52
▸ GLA P06280 2/20 0.50
▸ L3MBTL1 Q9Y468 1/20 0.50
▸ CASP7 P55210 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29669029 1.00 CYP1A2 (0.58) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL16185271 0.88 L3MBTL1 (0.51) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL20252672 0.87 ATM (0.52) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL319769 0.85 APLNR (0.58) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL16177694 0.81 CYP1A2 (0.62) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL31275112 0.80 KDM4C (0.57) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL15400259 0.79 APLNR (0.61) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL24963702 0.79 CYP1A2 (0.56) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL20238802 0.78 CYP1A2 (0.63) CYP1A2CYP3A4CYP2D6CYP2C19TSHR
SCHEMBL16109009 0.78 L3MBTL1 (0.74) CYP1A2CYP3A4CYP2D6CYP2C19TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110325531-B Benzenesulfonamides and their use as therapeutic agents 泽农医药公司 2022-05-27 — — CN disclosed
US-11299490-B2 Benzenesulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2022-04-12 — — US disclosed
US-11174268-B2 Benzenesulfonamide compouds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2021-11-16 — — US disclosed
US-11174268-B2 Benzenesulfonamide compouds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2021-11-16 — — US disclosed
US-20210171537-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2021-06-10 — — US disclosed
US-20210171537-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2021-06-10 — — US disclosed
CN-108349963-B Sodium channel blockers 株式会社大熊制药 2021-03-30 — — CN disclosed
CN-109526219-B Benzenesulfonamides and their use as therapeutic agents 泽农医药公司 2021-03-12 — — CN disclosed
US-20200354354-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS XENON PHARMACEUTICALS INC. (CA) 2020-11-12 — — US disclosed
US-10815229-B1 Benzenesulfonamide compounds and their use as therapeutic agents XENON PHARMACEUTICALS INC. (CA) 2020-10-27 — — US disclosed
WO-2014170792-A1 SULFONAMIDE DERIVATIVES AS URAT-1 INHIBITORS PFIZER LIMITED (GB) 2014-10-23 — — WO disclosed
US-8772293-B2 Chemical compounds PFIZER LIMITED (GB) 2014-07-08 — — US disclosed
US-8772293-B2 Chemical compounds PFIZER LIMITED (GB) 2014-07-08 — — US disclosed
US-8772293-B2 Chemical compounds PFIZER LIMITED (GB) 2014-07-08 — — US disclosed
EP-2590951-A1 BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS Pfizer Limited (GB) 2013-05-15 — — EP disclosed
WO-2012004743-A1 BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS PFIZER LIMITED (GB) 2012-01-12 — — WO disclosed
WO-2012004743-A1 BENZENESULFONAMIDES USEFUL AS SODIUM CHANNEL INHIBITORS PFIZER LIMITED (GB) 2012-01-12 — — WO disclosed
US-20120010182-A1 Chemical Compounds ICAGEN INC. (US) 2012-01-12 — — US disclosed
US-20120010182-A1 Chemical Compounds ICAGEN INC. (US) 2012-01-12 — — US disclosed
US-20120010182-A1 Chemical Compounds ICAGEN INC. (US) 2012-01-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10815229-B1 Benzenesulfonamide compounds and their use as therapeutic agents SCN1A, SCN1B, SCN2B CYP1A2 1091/4885CYP3A4 505/4885CYP2D6 321/4885
US-11174268-B2 Benzenesulfonamide compouds and their use as therapeutic agents KCND2, SCN1A, CACNA1D CYP1A2 831/4885CYP3A4 414/4885CYP2D6 285/4885
US-20120010182-A1 Chemical Compounds SCN1A, SCN1B, CACNA1E CYP1A2 643/4885CYP3A4 849/4885CYP2D6 580/4885
US-20210171537-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN1B, SCN2B CYP1A2 926/4885CYP3A4 396/4885CYP2D6 287/4885
US-11299490-B2 Benzenesulfonamide compounds and their use as therapeutic agents SCN1A, SCN1B, SCN2B CYP1A2 1091/4885CYP3A4 505/4885CYP2D6 321/4885
US-20200354354-A1 BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS SCN1A, SCN1B, SCN2B CYP1A2 1091/4885CYP3A4 505/4885CYP2D6 321/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.